Borrelia IgM and IgG antibody detection from DBS by ELISA (EUROIMMUN). Lyme disease clinical diagnosis.
This method detects IgM and IgG antibodies against Borrelia burgdorferi sensu lato species from a dried blood spot, supporting the clinical diagnosis of Lyme disease.
Clinical indications include:
IgM and IgG antibodies against Borrelia burgdorferi, B. afzelii, and B. garinii using the EUROIMMUN ELISA platform.
Antibodies are detected using the EUROIMMUN enzyme-linked immunosorbent assay (ELISA) platform, adapted for the DBS matrix. The assay uses recombinant antigens from the three main pathogenic Borrelia species prevalent in Europe and North America.
Borrelia is an important biomarker for clinical diagnosis of suspected lyme disease. Masdiag measures borrelia using validated analytical methods to provide clinically actionable results.
Borrelia testing is valuable for Clinical diagnosis of suspected Lyme disease, Detection of early (IgM) and late (IgG) immune response to Borrelia infection. Understanding borrelia levels helps inform personalized health optimization and clinical decision-making.
Borrelia collection is simple and convenient: prick your finger at home to collect a dried blood spot (DBS). This allows remote sampling without venepuncture.
This test is recommended for individuals interested in clinical diagnosis of suspected lyme disease. Masdiag borrelia testing helps guide personalized supplementation and health optimization strategies based on objective biomarker data.
Borrelia results provide insight into your metabolic status and clinical diagnosis of suspected lyme disease. Combined with clinical context, Masdiag results inform evidence-based interventions for personalized health optimization.
Whether you need testing services, method transfer, or white-label kit development — we'd love to hear from you.